The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|December 13, 2017
Dr. Landi on the Association Between Genetic Variance and Melanoma Risk
Author(s)Maria Teresa Landi, MD, PhD
Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.
Advertisement
Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.
In a large, global, meta-analysis of Caucasian patients, the association between genetic variance and risk of melanoma was evaluated.
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5